Outcomes Research

Stock Quotes for Outcomes Research top ^
  • Industry: Biotechnology
  • Sector: Healthcare
  • Stock Style: Small Core
Sign-up for cot investment picks

News Articles for Outcomes Research top ^
Eli Lilly and Company, Anthem, Inc. and HealthCore, Inc. announced today that they have formed a five-year, real-world evidence research collaboration intended to improve health outcomes for patients.
Sign-up for Lilly, Anthem, Inc. and HealthCore Create Research Collaboration to Improve Health Outcomes investment picks
Coverage gaps or caps on coverage generally did not result in health care savings Researchers urge policymakers to consider strategies other than limiting access to prescription drugs in efforts to reduce health care costs WOONSOCKET, R.I. , Jan.
Sign-up for CVS Health Research Institute Provides More Evidence that Broader Prescription Drug Coverage Improves Health Outcomes investment picks
ICON plc, (NASDAQ: ICLR) a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been awarded a project by the US Food & Drug Administration (FDA) to develop an industry-standard Patient Reported Outcome (PRO) measure that can be used in anti-bacterial drug development trials for hospital-acquired bacterial pneumonia (HABP). HABP is the second most common hospital-acquired infection and is the primary cause of death in intensive care units.
Sign-up for ICON Selected by the FDA to Develop New Patient-Reported Outcome Measure for Hospital-Acquired Bacterial Pneumonia Trials investment picks
Providing personalized health care to users of Medicare Supplement insurance, or “Medigap,” plan beneficiaries improved health outcomes, reduced care fragmentation and lowered costs for both Medicare and patients, according to recent analysis by Mercer of a pilot program.
Sign-up for Mercer: Patient-Centered Care Sees Positive Health Outcomes and Lower Costs for “Medigap” Population investment picks
Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, announced the launch of the BIOSENSE WEBSTER ADVANTAGE SM Program, an outcomes-based, risk-sharing program for U.S. hospitals that reinforces the significant patient benefits demonstrated by the company’s THERMOCOOL SMARTTOUCH ® Catheter.
Sign-up for Biosense Webster, Inc. Launches Outcomes-Based, Risk-Sharing Program to Reinforce Significant Patient Benefits Demonstrated by Company’s Leading Contact Force Therapy investment picks
The Medicines Company (NASDAQ:MDCO) today announced that data from two health economics analyses will be presented at the 17 th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) being held in Amsterdam, November 8-12.
Sign-up for Health Economic Data on The Medicines Company’s Infectious Disease and Cardiology Portfolios to be Presented at the 17th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) investment picks
http://media.marketwire.com/attachments/201204/36799_HP_Blue_RGB_72_MD.gif http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1162252&ProfileId=051205&sourceType=1 BARCELONA, SPAIN --
Sign-up for HP Launches New Enterprise Infrastructure Technology to Drive Positive Business Outcomes investment picks
Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced that it has received a positive outcome in the decentralized procedure for its new, three-times-a-week COPAXONE ® (glatiramer acetate) 40 mg/ml formulation for the treatment of adults with relapsing forms of multiple sclerosis (RMS). The outcome follows a Positive Assessment Report from the United Kingdom, the Reference Member State’s Medicines and Healthcare Products Regulatory Agency (MHRA), and all Concerned Member States (CMS) in Europe who were involved in the procedure.
Sign-up for Teva Receives Positive Outcome in Europe for Three-Times-a-Week COPAXONE® (Glatiramer Acetate) 40 mg/ml for the Treatment of Relapsing Forms of Multiple Sclerosis (RMS) investment picks
Foundation Medicine, Inc. (NASDAQ: FMI) and COTA, Inc. today announced an agreement to capture and analyze comprehensive genomic, clinical outcome, and cost data from patients who have undergone testing with FoundationOne ® .
Sign-up for Foundation Medicine Signs Data Partnership with Cancer Outcomes Tracking and Analysis (COTA, Inc.) to Inform Value-Based Cancer Treatment investment picks
New research in the international medical journal CHEST showed patients had reduced hospital stays, medical costs and returns to the hospital ABBOTT PARK, Ill., Nov.
Sign-up for People with Chronic Obstructive Pulmonary Disease (COPD) Who Received Nutrition Treatment in the Hospital Had Better Health Outcomes investment picks
Voip-Pal.com Inc. (“Voip-Pal”, “Company”) (OTC Pink: VPLM) announced today that the Board of Directors has unanimously passed a resolution to freeze any transfer of approximately 100,000,000 shares issued in 2013 to Locksmith Financial Corporation (“Locksmith”), pending the outcome of a recently conducted regulatory investigation.
Sign-up for Voip-Pal.com Board of Directors Unanimously Passes Resolution to Freeze the Transfer of Approximately 100 Million Restricted Shares Issued to Locksmith Financial Corporation Pending the Outcome of an Investigation investment picks
Sign-up for IBM Unveils Cognitive Exploration to Drive Better Business Outcomes investment picks
http://media.marketwire.com/attachments/201501/83212_masimo.jpg http://media.marketwire.com/attachments/201501/83213_inova.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1169174&ProfileId=051205&sourceType=1 FAIRFAX, VA and IRVINE, CA --
Sign-up for Inova Fair Oaks Hospital Casts Masimo Patient SafetyNet(TM) to Help Improve Patient Outcomes and Reduce Costs investment picks
Partnership to Provide Students Learning Tools Designed to Help Students Persist and Graduate at Higher Rates SANTA CLARA, Calif.
Sign-up for Chegg Integrates Into Blackboard Learn To Help Improve Student Outcomes investment picks
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) (“Eagle” or the “Company”) today announced positive results from a recently-conducted clinical trial of its bendamustine hydrochloride (“HCl”) product, in which the dose was delivered in a 50mL admixture in ten minutes (the “rapidly infused product”) versus a 500mL admixture in the 60-minute infusion required for Treanda ® (bendamustine HCl). In this study, Eagle’s rapidly infused product was found to be bioequivalent to Treanda, which was the primary endpoint of the study.
Sign-up for Eagle Pharmaceuticals Reports Positive Outcomes from Clinical Trial of Bendamustine HCl Product Delivered via Low-Volume, Rapidly Infused Admixture investment picks
Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, this week recognizes the 10 th anniversary of its unique Equinoxe ® Shoulder System .
Sign-up for Industry’s Fastest Growing Shoulder System Marks 10 Years of Improving Patient Outcomes investment picks
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that researchers presented data from clinical trials of Soliris ® (eculizumab) in patients with atypical hemolytic uremic syndrome (aHUS), as well as an update from the Global aHUS Registry, at Kidney Week 2014, the annual meeting of the American Society of Nephrology, in Philadelphia.
Sign-up for Longer-term Outcome Data from the Largest Prospective Trial of Soliris® (eculizumab) in aHUS Underscore the Effectiveness of Ongoing Soliris Treatment investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar

Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Outcomes Research
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Outcome-Based Research  |  Next: Outdoor Recreational Stocks